September 27, 2016
Launch of LUMICEF® for Psoriasis Treatment, in Japan
Tokyo, Japan, September 27th, 2016 --- Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151, President and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") announced today that LUMICEF® Subcutaneous Injection 210 mg Syringe will be launched in Japan on September 30th, 2016.
LUMICEF® is a novel fully human anti-interleukin-17 (IL-17) receptor A antibody that inhibits biological activity of IL-17A, IL-17F and other IL-17s. LUMICEF® was listed on the National Health Insurance (NHI) Drug Price List on August 31st , 2016 after the manufacturing and marketing approval in Japan on July 4th , 2016. LUMICEF® is expected to improve the clinical symptoms of patients with the approved indications.
"We are very pleased to announce the launch of LUMICEF® in Japan, the first launch worldwide" said Hiroshi Sugitani, Managing Executive Officer, Vice President Head of Sales & Marketing Division of Kyowa Hakko Kirin. "We believe that LUMICEF® will provide a new therapeutic option for the treatment of psoriasis and will greatly contribute to better improvement of treatment satisfaction and improved QOL (quality of life) in patients with psoriasis".
The Kyowa Hakko Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.
|Product Name||LUMICEF® Subcutaneous Injection 210 mg Syringe|
|Generic Name||Brodalumab (Genetical Recombination)|
|Indications||The following diseases that respond inadequately to existing therapies; Psoriasis vulgaris, psoriatic arthritis, pustular psoriasis, and psoriatic erythroderma.|
|Dosage and administration||In adults, administer 210 mg subcutaneously as brodalumab (Genetical Recombination) at Weeks 0, 1, and 2, followed by 210 mg every 2 weeks.|
|Package||LUMICEF® Subcutaneous Injection 210 mg / 1 Syringe|
|Date of approval||July 4th , 2016|
|Date of NHI price listing||August 31st , 2016|
|NHI drug price||73,158 Yen / 1 Syringe|
Psoriasis is a chronic skin disorder. Typical symptoms include systemic erythema with clearly demarcated lesions, induration and hyperplasia inducing silver white plaques on the skin. Itching, inflammatory arthritis and abnormal nail morphology may also manifest.
About IL-17 receptor A
Interleukin-17 receptor A is a component of the receptor for IL-17A, IL-17A/F, IL-17F and IL-17C. These pro-inflammatory cytokines are thought to contribute to the pathophysiology associated with psoriasis.
IL-17A, IL-17F and other IL-17s are pro-inflammatory cytokines thought to be involved in autoimmune diseases including psoriasis.